Pure Global

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors - Trial NCT06214143

Access comprehensive clinical trial information for NCT06214143 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 68 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06214143
Phase 1/2
Recruiting
biological
Trial Details
ClinicalTrials.gov • NCT06214143
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Study Focus

Advanced Solid Tumors

T3011 high dose

Interventional

biological

Sponsor & Location

Shanghai Pharmaceuticals Holding Co., Ltd

Anyang,Bengbu,Changsha,Chengdu,Dongwan,Fuzhou,Guangzhou,Guangzhou,Ha'erbin,Hangzhou,Hangzhou,Jinan,Nanchang,Nanning,Shanghai,Shanghai,Shenyang,Shenzhen,Taiyuan,Tianjin,Wuhan,Zhengzhou, China

Timeline & Enrollment

Phase 1/2

Jan 11, 2024

May 31, 2026

68 participants

Primary Outcome

Incidence of Treatment-Emergent Adverse Events,Objective response rate(ORR)

Summary

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1
 inhibitors in subjects with advanced solid tumors

ICD-10 Classifications

Malignant neoplasm: Prepuce
Carcinoma in situ, unspecified
Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm: Orbit

Data Source

ClinicalTrials.gov

NCT06214143

Non-Device Trial